Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

All Systems Go! For Geron And JNJ In Both iMerge And iMbark Trials For MF And MDS

|About: Geron Corporation (GERN), JNJ
Summary

Median Overall Survival Keeps Growing In Unprecedented 23+ Months In The Myelofibrosis iMbark Trial.

iMerge Part 1 Expansion Phase is now beyond critical 8 Week point for transfusion independence.

Shorts run out of supply for stocks to cover as 2015 ATM program is now complete; shares available will now dry up very quickly.

Today's Q4 announcement confirms the strong collaboration between Geron (GERN) and Johnson and Johnson (JNJ) remains strong and is moving forward.  Median Overall Survival has not yet been reached in the Myelofibrosis "MF" trial iMbark and iMerge has now passed the 8 week critical point.  All systems go, as they say, for the collaboration and for Geron shareholders.

Median Overall Survival Keeps Growing In Unprecedented 23+ Months In The Myelofibrosis iMbark Trial.

Q4 is complete and we are now into at least the 23rd month of Median Overal Survival and counting.  Keep  in mind the patient pool in the iMbark trial is closest to the 7-8 month median overal survival group CEO Dr. Scarlett mentioned at the Q3 conference call. The company now has sufficient data to make a compelling case for Accelerated Approval for Myelofibrosis patients Refractory to or Relapsed from Jak inhibitors.  Upon approval, Imetelstat is likely to exceed Jak inhibitor sales  ($1Billion) in Myelofibrosis by the second year in commercialization.

iMerge Part 1 Expansion Phase is now beyond critical 8 Week point for transfusion independence.

The expansion phase is now beyond the critical 8 week point for transfusion independence and the company likely now has sufficient data to submit an application for Accelerated Approval in MDS. MDS market is approximately 3 times larger than MF.

Shorts run out of supply for stocks to cover as 2015 ATM program is now complete; shares available will now dry up very quickly.

Shares will likely climb sharply ahead of next weeks Annual Shareholders meeting in Menlo Park headquarters and will probably continue to run from there.  We are now at a critical inflection point and everything is aligning in shareholders favor.  Short sellers are now without the largest source of predictable shares to cover, this after the reason second bump over 40MM short shares.  Since the average selling price for the 2015 ATM program that has gone on for quite a long time now was about $3.62 per share, the shorts were able to dull the run over $4 per share in April.  This is no longer an option for shorts, they have nowhere to turn, they are now out of options.

All Systems Go!

Disclosure: I am/we are long GERN.